Powder: -20°C for 3 years | In solvent: -80°C for 1 year
SPR206 acetate is a polymyxin analog that exhibits antibiotic activity against Gram-negative pathogens, including multidrug-resistant (MDR) variants. By interacting with the outer membrane of the bacterium, SPR206 acetate effectively combats bacterial infections. Notably, SPR206 acetate demonstrates significant efficacy with minimum inhibitory concentration (MIC) values of 0.125 mg/L against Pseudomonas aeruginosa Pa14 and Acinetobacter baumannii NCTC13301.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Inquiry | $ 789.00 | |
10 mg | Inquiry | $ 1,240.00 | |
50 mg | Inquiry | $ 3,480.00 |
Description | SPR206 acetate is a polymyxin analog that exhibits antibiotic activity against Gram-negative pathogens, including multidrug-resistant (MDR) variants. By interacting with the outer membrane of the bacterium, SPR206 acetate effectively combats bacterial infections. Notably, SPR206 acetate demonstrates significant efficacy with minimum inhibitory concentration (MIC) values of 0.125 mg/L against Pseudomonas aeruginosa Pa14 and Acinetobacter baumannii NCTC13301. |
Targets&IC50 | Pseudomonas aeruginosaPa14:0.125 mg/L (MIC), Acinetobacter baumanniiNCTC13301:0.125 mg/L (MIC) |
In vitro | SPR206 demonstrates potent anti-microbial activity against Gram-negative bacteria, displaying Minimum Inhibitory Concentration (MIC) values of 8 mg/L for E. coli IHMA558090, 0.125 mg/L for E. coli ATCC 25922, 0.125 mg/L for K. pneumoniae ATCC 13882, 0.25 mg/L for P. aeruginosa ATCC 27853, 0.06 mg/L for A. baumannii NCTC13424, and 0.125 mg/L for A. baumannii ATCC 19003. This is coupled with reduced cytotoxicity[1]. |
In vivo | Treatment with SPR206 administered at dosages ranging from 0.125 to 30 mg/kg, either through intravenous or subcutaneous injection every 4 or 8 hours over a period of 16 to 24 hours, was found to effectively reduce the burden of Pa14 and NCTC13301 in the lung tissue and thigh model of neutropenic mice. Specifically, in the lung tissue, SPR206 reduced the concentrations of Pa14 and NCTC13301 by 1.5 and 3.6 log10 CFU/mL, respectively. In the thigh model, it decreased the concentration of Ab13301 by 3.4 and 4.3 log10 CFU/g. This demonstrates SPR206’s potential efficacy in treating infections caused by these pathogens in neutropenic mouse models. |
Molecular Weight | N/A |
CAS No. | 2408422-41-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
SPR206 acetate 2408422-41-1 SPR 206 Acetate SPR-206 Acetate SPR-206 acetate SPR206 Acetate inhibitor inhibit